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ANDROGEN RECEPTOR AMPLIFICATION
The significance of androgens in the development 
of prostate cancer has been known for more than half 
century. During the last decade, a lot of efforts has 
been made to study the significance of the specific 
nuclear receptor of the hormone, androgen recep-
tor (AR). It has been suggested that polymorphisms, 
especially the length of CAG repeat in exon 1 of the 
gene, are associated with the risk of prostate cancer. 
However, not all studies have confirmed the associa-
tion. Most surprisingly, it has now become clear that 
prostate carcinomas emerging during the androgen 
withdrawal therapy (i. e. hormone-refractory tumors) 
are capable of reactivating the AR-mediated signaling 
despite of the low levels of androgens. In addition, it has 
been shown that AR gene itself is genetically targeted. 
Androgen receptor gene amplification (ARGA) has 
been suggested as one of the molecular mechanisms 
responsible for the development of hormone refractory 
prostate cancer. Progression of prostate cancer during 
endocrine therapy is a major clinical problem, the mo-
lecular mechanisms of which remain poorly understood. 
Amplification of the AR gene was recently described 
in recurrent prostate carcinomas from patients who had 
failed androgen deprivation therapy [1, 2]. According 
to several studies, the frequency of ARGA is stemmed 
to be around 30%. On the other hand, insignificant dif-
ferences were found between AR expression in tumors 
with and without gene amplification and not all prostate 
tumors with ARGA showed increased levels of the 
AR protein. These data suggest that other mechanisms 
apart from AR amplification are involved in the progres-
sion of prostate cancer. An association between ARGA 
and response to therapy has been demonstrated. 
In patients who assumed combined androgen blockade 
after initial androgen deprivation, a major response 
was observed in those with ARGA than in those without 
ARGA [2, 3]. In the same study decreased PSA levels 
were found in patients with ARGA compared to patients 
without it [1, 2]. In contrast, in the bibliography we find 
evidence that between PSA expression and ARGA any 
correlation might exist. To establish the link between 
prostate specific antigen PSA and gene amplification 
further investigations are required. During neoplastic 
progression, other gene amplification such as p53, myc, 
CCND1 or ErbB2 may occur. A recent study provides 
evidence of an increasing p53 expression during pro-
gression from an androgen dependent to an androgen 
independent prostate cancer, and positive p53+ tumors 
were found more frequently in patients with ARGA than 
in patients without it. Furthermore, amplification of myc 
and ARGA genes was detected in 11% and 22% cases, 
respectively in metastases from patients with hormone-
refractory prostate cancer, in comparison to locally 
recurrent tumors (4–23%). In summary, neoplastic 
progression depends on the accumulation of multiple 
genetic alterations some of which may occur at early 
stages and others — at late ones. Each molecular event 
can influence cell-cycle and apoptosis, and may play 
a role as prognostic factor in prostate cancer [4–6].
CO-REGULATORS
There is an evidence that the AR transcriptional 
activity is influenced by several co-regulators. These 
molecules can either up-regulate (co-activators) 
or down-regulate (co-repressors) the AR transcrip-
tional status, usually in a ligand-dependent manner 
and generally without binding to DNA. Some of them 
such as cyclic AMP binding protein (CBP)/p300 and 
steroid receptor coactivator-1 (SRC-1) can induce 
DNA modification recruiting the CBP/p300-associated 
factor, which possesses histone acetyltransferase 
(HAT) activity. Furthermore, the finding that hydroxy-
flutamide can increase AR activity when CBP is over 
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expressed confirms the hypothesis that co-regulators 
can interfere with the effects of antiandrogens by al-
tering the AR ligand specificity and thus contributing 
to the progression of prostate cancer [7, 8]. Various 
studies reported different results regarding the co-
regulators expression in prostate cancer. Scientists 
by using RT-PCR method found that ARA54, ARA70, 
and SRC-1 were expressed in both tumor and normal 
cultured prostate cells. ARA55 was not expressed 
in androgen-independent LNCaP and DU145 prostate 
cancer cell lines, while its very low levels were detected 
in PNT2 cell line [9, 10]. Additionally, other studies have 
demonstrated, by the method of in situ hydritization, 
higher levels of the co-regulator Ran/ARA24 in pros-
tate tumor specimens. In contrast, other scientists 
did not find overexpression of ARA24 using RT-PCR 
in prostate cancer xenografts and cell lines. Perhaps 
this discrepancy could be explained by the fact that 
in situ hydritization is a poor quantitative method. 
Also, SRC-1 expression appeared to be reduced. This 
finding correspondes to the results of another group 
of scientists who demonstrated lower SRC-1 expres-
sion in hormone refractory LNCaP cells in comparison 
to hormone dependent LNCaP cells [9–11]. In contrast, 
another study detected elevated levels of SRC-1 pro-
tein in androgen independent prostate cancer [10, 12]. 
Differences in cell cultures conditions, cell density, 
methods of analysis and various types of cell lines may 
explain these divergent results. However the weight 
of evidence sustains the expression and the biological 
role of co-regulators in AR modulation and promotion 
to advanced prostate cancer.
ARA54
Ara54 is a protein of 474 aminoacids and molecular 
weight of 54kDa that is shown to increase AR tran-
scriptional activity in a DU145 cell line. ARA54 contains 
a conserved RING finger motif and a B-box like struc-
ture. It has been reported that the C-terminal region, 
without the RING finger motif, may exert inhibitory ef-
fect on AR-mediated transactivation. ARA54 may also 
enhance the transcriptional status of LNCaP mutant 
AR (ART877a) but not wild type AR or another mutant 
AR (Are708k). A mutant ARA54 form (mt-ARA54), 
with a point mutation at aminoacid 472 and incapable 
to bind to AR, can suppress the positive AR trans-
activation of endogenous or exogenous full-length 
f-l ARA54. Furthermore, the inhibition was higher for 
exogenous f-l ARA54 in DU145 cells than for endoge-
nous in PC-3 and LNCaP cells, probably because 
of the intervention of other coactivators in PC-3 and 
NCaP cells. Moreover, mt-ARA54 disrupts the inter-
action between lf-ARA54 and fl-ARA54 molecules 
by forming dimers with fl-ARA54, suggesting that 
ARA54 may need to form homodimers to increase 
AR transcriptional status. These findings underline that 
dominant-negative mutant forms of ARA54 or of other 
co-regulators, should be considered as potential tar-
gets for prostate cancer therapy [9, 13].
ARA55
ARA55 consists of 444 aminoacids and has a molecu-
lar weight of 55 kDa. There is a sequence homology bet-
ween human ARA55 gene and mouse TGF-β1 inducible 
gene hic-5. ARA55 seems to have a role in the stromal 
epithelial interaction involved in developing human fetal 
prostate. ARA 55 was found to be expressed in stromal 
cells with a zonal pattern, primarily in the peripheral zone 
surrounding the non canalized acini. Tissue distribution 
studies suggest that ARA55 may be differentially ex-
pressed during various stages of prostate cancer. Higher 
ARA55 levels were detected in tissue specimens from 
androgen-independent prostate cancers than in those 
from androgen-dependent prostate cancers [10, 14, 
15]. In contrast, using RT-PCR scientists found lower 
ARA55 levels in the tissue samples of androgen-indepen-
dent prostate cancers in comparison to untreated pros-
tate cancers or benign prostatic hypertrophy specimens 
[16]. On the other hand, higher ARA55 expression levels 
in patients with androgen — independent prostate cancer 
were associated with shorter recurrence free survival and 
overall survival. ARA55 is able to bind to AR in a ligand-
dependent manner and increase its transcriptional status. 
The interaction occurs via the C-terminal half of ARA55, 
which includes three LIM motifs. Also it has been reported 
that ARA55 can induce AR transactivation in response 
to antiandrogens like hydroxyflutamide and other non an-
drogenic steroids including 17β-estradiol. In LNCaP cells, 
a dominant-negative AR associated protein (dARA55) 
co-regulator inhibits the AR transcriptional activity and re-
duces the agonistic action of antiandrogens. dARA55 also 
inhibits PSA expression and prostate cancer cell proli-
feration and therefore, should be considered as a gene 
therapeutic agent [14–16]. A correlation was found be-
tween ARA55 and proline-rich tyrosine kinase 2 (Pyk2). 
Pyk2 is a member of the focal adhesion kinase (FAK) 
family and may be linked to the mitogen activated protein 
(MAP) kinase and JNK signaling pathways. As it was de-
monstrated in human prostate cancer cell lines, Pyk2 can 
directly phosphorylate ARA 55 at tyrosine 43, resulting 
in its inactivation. The inactivation may occur either 
by impairment of the activity or by sequestration of the 
co-activator, and the consequence is the suppression 
of the AR transcriptional action. However, the phospho-
rylation site is not found in the AR interaction domain 
of ARA55 (aminoacids 251–444), suggesting that other 
mechanisms could be involved in the suppression of the 
AR transactivation [17, 18].
ARA70
ARA70, found in a DU-145 prostate cancer cell 
line, was the first AR co-regulator identified. There 
is a growing evidence that this protein may be impli-
cated in the enhancement of the AR transcriptional 
activity through a specific ligand binding. It is reported, 
that it can also increase the transcriptional activity 
of other steroid receptors like the glucocorticoid re-
ceptor (GR), progesterone receptor (PR) and estro-
gen receptor (ER). However, the levels are increased 
slightly (up to 2-fold) in comparison to the enhance-
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ment of AR (up to 10-fold). One study showed that the 
consensus FXXLF motif within the ARA 70-N2 domain 
(aminoacids 176–401) is important for the interaction 
with the AR. The LXXLL motifs, essential for the function 
of co-regulators such as the p160 co-regulator, do not 
have an important role in ARA70 interaction [19–21].
Whether this molecule is involved in the progres-
sion of prostate cancer is of relevant interest. The 
detection of ARA70 in AR-positive LNCaP cells but not 
in AR-negative DU 145 cells probably indicates a modifi-
cation of expression and ability to interact with AR during 
the progression of prostate cancer from a hormone-
sensitive to a hormone-insensitive state. Recently, 
elevated ARA70 expression was found in high grade 
prostate cancer tissues as well as in hormone refrac-
tory LNCaP xenografts and prostate cancer cell lines. 
Moreover, higher ARA70 protein levels (91.74%) were 
detected in prostate cancer specimens than in benign 
tissue (64.64%). In addition, one study demonstrated 
enhanced ARA70 mRNA levels in a recurrent androgen-
independent CWR22 prostate cancer xenograft, derived 
from an androgen-stimulated state after castration. 
ARA 70 has been extensively examined as a molecule 
that may potentiate AR transcriptional activity not only 
in the presence of androgens but also in the pre sence 
of antiandrogens and 17β estradiol [20]. Several stu-
dies of HeLa, PC3 and TSU-Pr1 cell lines establish 
the induction of AR by 17β estradiol in the presence 
of ARA70. However, the results of two different studies 
in CV-1 cells regarding ARA70 and 17β estradiol — me-
diated AR transactivation are contradictory. The reason 
of these opposing results is not yet known. Prostate 
cancer may continue to proliferate in response to an-
tiandrogens (hydroxyflutamide and bicalutamide) and 
the role of ARA 70 is critical for this process. In LNCaP 
cell line, the addition of a dominant negative AR co-
regulator ARA 70 (aARA70N), lacking AR interaction, 
blocks the ARA70-enhanced AR transcriptional activity 
by forming a non-functional heteromer with ARA70. The 
RNA-interference-mediated silencing of ARA70 gene 
confirms this observation [19, 20–23].
ARA267-a
ARA267-a is an AR co-regulator containing the 
SET domain with 130 aminoacid motif named from 
three originally identified proteins, Su(var)3–9, 
Enhancer-of-zeste and Thritorax. It also contains 
two LXXLL motifs, three nuclear translocation signal 
(NLS) sequences and four plant homodomain (PHD) 
finger domains. Recent data show that ARA267-a can 
increase the AR transactivation in prostate cancer 
cells, probably by binding to DNA and remodeling 
of chromatin structure. The SET domain and the PHD 
fingers may play important roles in AR-mediated 
gene transcription. In addition, it can not be excluded 
that the LXXLL motifs, motifs essential for the func-
tion of the co-regulators SRC-1 and TIFII, may also 
be important for the ARA267-a function. Finally, ac-
cording to the results of a recent study, an interaction 
between DR6cp (a member of the TNF receptor family 
that mediate cell apoptosis) and ARA267-a fragment 
containing four PHD and one SET conserved domains 
may occur, suggesting a possible cross-talk between 
the apoptosis signaling pathway and the androgen 
signaling pathway [24–26].
ART-27
Art-27, a small protein of 157 aminoacids and 
with molecular weight of 18 kDa, is a newly identified 
AR N-terminal coactivator that increases receptor-
dependent transcriptional activity. It seems to interact 
predominantly with the AR aminoacids 153–336, con-
taining AF-1a and a part of AF-1b. Art-27 is expressed 
in a variety of human tissues sensitive to androgen 
action such as prostate, breast and skeletal muscle. 
According to the results of some studies, Art-27 pro-
motes epithelial prostate cell differentiation and inhi-
bits proliferation. In human prostate cancer cells this 
protein in not markedly expressed. In LNCaP transfec-
ted cell line, the reintroduction of Art-27 reduced cell 
proliferation and upregulated the androgen-mediated 
transcription of the PSA gene, a gene that is activated 
in differentiated epithelial prostate cells. The mecha-
nism by which Art-27 is regulated is unclear. However, 
androgens might not directly control its expression be-
cause of the restricted cell-type distribution of Art-27. 
Moreover, addition of androgens in LNCaP cell line did 
not induce Art-27 expression. The altered Art-27 ex-
pression during prostate cancer progression should 
be an object of further analysis [27–29].
β-Catenin
β-Catenin contains five LXXLL motifs situated in the 
central core region containing the armadillo repeats. 
This region is required for the β-catenin interaction 
with E-cadherin and members of the T-cell factor (TCF) 
and lymphoid enhancer factor (LEF) family, thus initia-
ting the transcription of the Wnt/Wingless-responsive 
genes [30, 31]. The Wnt/Wingless signaling pathway 
apart of its role in regulating cell processes such 
as proliferation, polarity and migration, is also involved 
in oncogenesis. 80% of colon cancers present elevated 
β-catenin-TCF signaling. Moreover, it has been de-
monstrated that β-catenin mutations can occur in more 
than 50% of colon cancer cases and in more than 50% 
of hepatoblastoma cases. β-catenin mutations were 
detected in 5% of prostate cancer tissue samples. Four 
of them are located in the serine or theonine residues 
implicated in the degradation of β-catenin and one 
(the codon 32) changes aspartic acid to a tyrosine. 
The mutations occurred focally and therefore should 
be considered as a late event in prostate cancer 
progression. β-catenin can regulate AR function and 
contribute to the prostate cancer progression despite 
low levels of endogenous androgens, by modulating 
receptor-dependent signaling. In LNCaP cell line, 
β-catenin (β-catenin S33F) can relieve the inhibitory 
effects of the antiandrogen bicalutamide and increase 
the poor action to the androgen androstenedione 
on AR transactivation to a level comparable to DHT. Cor-
relation between β-catenin and other steroid receptors 
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is possible: it increases the transcriptional activity of the 
retinoic acid receptor [31, 32].
FHL2
Four and a half LIM domains 2 (FHL2), a LIM pro-
tein, is the first tissue-specific co-activator of the AR. 
As it was shown for prostate epithelial cell and the 
myocardium of the heart, FHL2 is able to enhance the 
AR transactivation in an agonist- and AF-2-dependent 
manner. The interaction between FHL2 and AR requires 
both the N- and C-terminus of the AR. There is also evi-
dence of an interaction between FHL2 and β-catenin. 
Although no synergistic action on AR transcriptional 
activity was observed in prostatic cell cultures, the 
activation of the cyclin D1 promoter is mediated 
by FHL2 in a β-catenin dependent manner in liver tu-
mors. It was shown that the Rho signaling pathway 
induces activation and nuclear translocation of FHL2, 
because AR-dependent genes activation and the the 
N-terminal of FHL2 are required for this process. In ad-
dition, Rho GTP-ases overexpression and FHL2 nuclear 
localization correlate with a lower differentiation grade 
of prostate tumor. Therefore, it would be interesting 
to examine the contribution of FHL2 to AR function and 
prostate cancer progression [33–36].
Her2/NEU
Her2/Neu, a transmembrane glycoprotein with 
intrinsic tyrosine kinase activity, is a member of the epi-
dermal growth factor receptors family (EGFR). Over-
expression of Her2/Neu was found in 30% of breast 
and ovarian cancers. Contrasting results of various 
studies regarding the Her2/Neu gene product ex-
pression are reported, probably due to differences 
in the reagents, lack of standardized techniques and 
different scoring methodologies. Moreover, by several 
researches a varying degree of Her2/Neu gene ampli-
fication was shown. However, according to the recent 
reports, Her2/Neu is implicated in the enhancement 
of AR transactivation and progression to an androgen-
resistant stage of prostate cancer [37, 38].
ErbB2 is able to signal in the absence of ligand by di-
merization leading to autophosphorylation and initiation 
of specific signal transduction cascades. There are two 
known transduction pathways by which Her2/Neu may 
lead to androgen-independent prostate cancer: the 
PI3K/Akt and the MAPK pathway. The Akt activation was 
examined in LNCaP co-trasfected cell line. It was found 
that Akt can be activated by Her2/Neu in the absence 
of androgens and that Akt can induce AR transactivation 
promoting the development of an androgen-indepen-
dent growth of prostate cancer cells [39, 40]. In fact, 
growth inhibitory effects were observed when the Akt 
inhibitor LY294002 was added. According to the above-
mentioned studies, the amino acids at sites 213 and 
791 of the AR are phosphorylated by Akt. In addition, 
Akt may increase the PSA transcription by activating 
the PSA gene promoter. On the other hand, enhance-
ment of the PSA levels and AR activity induced by Her2/
Neu via the MAPK pathway were detected in LNCaP 
and DU145 prostate cancer cell lines. It is possible 
that the phosphorylation site(s) of the AR are located 
in the hormone-independent N-terminal region. Since 
there is evidence that Her2/Neu may be associated 
with an androgen-independent prostate cancer, nume-
rous therapeutical molecules targeting this tyrosine 
kinase are in trial [39–44]. Trastuzumab (Herceptin), 
a monoclonal antibody directed against the extracellular 
domain of the Her2/Neu protein, presents antitumor 
activity in androgen-independent prostate cancer xe-
nografts. Trastuzumab in association with paclitaxel, 
a chemotherapeutic agent, had also high antitumor 
properties against androgen-independent prostate 
cancer. Other monoclonal antibodies (MDX-H210 with 
GM-CSF) have been tested also with positive antipro-
liferative properties in DU145 and PC-3 prostate can-
cer cell lines since Her2/Neu protein expression was 
downregulated. Finally, an ansamycin antibiotic, the 
17-Allylamino-17-demethoxygeldanamycin (17-AAG), 
can cause degradation of Her2/Neu, Akt and AR. 
Inhibiting action of 17-AAG was observed in prostate 
cancer xenografts.
IL-6
IL-6, a cytokine with pleiotropic functions, plays 
an important role in the physiopathology of prostate 
cancer. Elevated IL-6 levels in the sera of patients 
with prostate cancer are associated with high mortali-
ty, poor prognosis and AR transactivation. IL-6 can 
modulate the growth of malignant cells through at least 
three distinct signaling pathways including JAK/STAT3, 
MAPK and PI3K/Akt [39, 40]. However, until now the 
data regarding the effects of IL-6 on prostate can-
cer remain controversial, probably because of the 
coexistence of these multiple pathways with either 
positive or negative influence on each other. In LNCaP 
cells, in the absence of androgens, IL-6 can increase 
AR gene expression and activate the AR. In addition, 
the application of several MAPK inhibitors blocked the 
IL-6- mediated induction of the androgen-responsive 
promoter, demonstrating that IL-6 activity depends 
on MAPK pathway. Many other studies report growth 
stimulating effects of IL-6 [40, 41, 44]. In contrast, 
some investigators found that IL-6 inhibits the access 
of the coregulator p300 to the complex p160-PSA 
promoter with consequent inhibition of histone acety-
lation [45, 46]. They also found that IL-6 inhibited the 
PSA gene expression, at least in part, through the 
STAT3 pathway without MAPK and PI3K/Akt involve-
ment [46]. The reason for these opposite results 
is unknown. One study demonstrated that in LNCaP 
cells, IL-6 can induce G1 growth arrest reflected in de-
creasing levels of cyclin-dependent kinase-2 (CDK2), 
-4 (CDK4), and -6 (CDK6). In addition, the LNCaP cells 
underwent neuroendocrine differentiation. Neuroen-
docrine-like differentiation as a result of treatment with 
IL-6 was also observed by another group of scientists 
in an LNCaP cell line. Moreover, the scientists found 
that androgens-ARs can block neuroendocrine dif-
ferentiation by inhibiting the IL-6 mediated PI3K/Akt 
pathway [39–41, 45, 46].
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CONCLUSION
Growth of the prostate malignant cells highly de-
pends on the androgens presence. ARGA represents 
one of the molecular mechanisms involved in the 
development of hormone refractory prostate cancer. 
AR trancriptional activity is influenced by a number of co-
regulators. Co-activators and co-repressors impair the 
AR transcriptional status, which in return affect the whole 
process of prostate carcinogenesis. ARA54, ARA55, 
ARA70, ARA 267-a, ART-27 as well as β-catenin, FHL-2, 
Her2/Neu and IL-6, represent the most important and 
well-studied co-regulator proteins.
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